Ramipril Patent Invalid Due To Obviousness: Court

Law360, New York (September 11, 2007, 12:00 AM EDT) -- An appeals court ruled on Tuesday that King Pharmaceutical's patent on its hypertension drug Altace was obvious and thus invalid, overturning a lower court's ruling that generics maker Lupin LTD infringed on the patent.

King, along with German drug maker Aventis Pharma Deuschland GMBH, originally filed a suit against Lupin after Lupin filed an Abbreviated New Drug Application to make a generic version of Altace.

A Virginia district court ruled last year that Lupin's generic drug would have infringed, though it dismissed King and Aventis' claim...
To view the full article, register now.